Replication of the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Diabetes Trial in Healthcare Claims
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 49,790
- 试验地点
- 1
- 主要终点
- Composite outcome of Stroke, MI, and Mortality
研究概览
简要总结
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
详细描述
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent prior to any study specific procedures (including run-in)
- •Female or male aged ≥ 40 years
- •Diagnosed with T2DM
- •High Risk for CV event defined as having either established CV disease and/or multiple risk factors:
- •Established CV Disease (See Appendix E for details) OR No known cardiovascular disease AND at least two cardiovascular risk factors in addition to
- •T2DM, defined as:
- •Age > 55 years in men and > 60 in women AND presence of at least 1 of the following additional risk factors (see Appendix E for details)
- •Dyslipidemia
- •Hypertension
- •Tobacco use
- •WOCBP must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose.
- •WOCBP must have a negative urine pregnancy test. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal.
- •WOCBP must be willing to use a medically accepted method of contraception that is considered reliable in the judgment of the Investigator. For inclusion in the optional genetic research, patients must fulfill the criterion specified in
排除标准
- •Patients should not meet any exclusion criteria at the time of randomization. If at the time of enrollment, it is known that the patient will not meet criteria after a successful run-in period he/she should not be entered into run in.
- •Use of the following excluded medications:
- •Current or recent (within 24 months) treatment with pioglitazone and/or use of pioglitazone for 2 years or more at any time
- •Current or recent (within 12 months) treatment with rosiglitazone
- •Previous treatment with any SGLT2 inhibitor
- •Any patient currently receiving chronic (>30 consecutive days) treatment with an oral steroid at a dose equivalent to oral prednisolone ≥10 mg (e.g., betamethasone ≥1.2 mg, dexamethasone ≥1.5 mg, hydrocortisone ≥40 mg) per day
- •Acute cardiovascular event [e.g., acute coronary syndrome (ACS), transient ischemic attack (TIA), stroke, any revascularization, decompensated HF, sustained tachycardia <8 weeks prior to randomization. Patients with acute cardiovascular events can be enrolled in the run-in period as long as randomization does not occur within 8 weeks of the event.
- •Systolic BP >180 or diastolic BP >100 mmHg at randomization
- •Diagnosis of Type 1 diabetes mellitus, MODY, or secondary diabetes mellitus
- •History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
- •History of any other malignancy within 5 years (with the exception of successfully treated non-melanoma skin cancers)
- •Chronic cystitis and/or recurrent urinary tract infections (3 or more in the last year)
- •Any conditions that, in the opinion of the Investigator, may render the patient unable to complete the study including but not limited to cardiovascular (NYHA class IV CHF, recurrent ventricular arrhythmias) or non-cardiovascular disease (e.g., active malignancy with the exception of basal cell carcinoma, cirrhosis, chronic lung disease, severe autoimmune disease) and/or a likely fatal outcome within 5 years
- •Pregnant or breast-feeding patients
- •Involvement in the planning and/or conduct of the study or other dapagliflozin studies (applies to AZ, BMS, Hadassah and Thrombolysis in Myocardial Infarction [TIMI] or representative staff and/or staff at the study site)
- •Previous randomization in the present study
- •Active participation in another clinical study with IP and/or investigational device
- •Individuals at risk for poor protocol or medication compliance during run-in period (reasonable compliance defined as 80 - 120%, unless a reason for non-compliance is judged acceptable by the Investigator). If for any reason, the Investigator believes that the patient will not tolerate or be compliant with IP or study procedures, the patient should not be randomized and considered a run-in failure. Patients will be excluded during run-in and should not be randomized if the following are observed from laboratory or observation during enrollment and run-in assessments:
- •HbA1c ≥12% or HbA1c<6.5%
- •AST or ALT >3x ULN or Total bilirubin >2.5 x ULN
- •CrCl < 60 ml/min (based on the Cockroft-Gault equation)
- •Hematuria (confirmed by microscopy at Visit 1) with no explanation as judged by the Investigator up to randomization. If bladder cancer is identified, patients are not eligible to participate.
- •Any reason the Investigator believes the patient is not likely to be compliant with the study medication and protocol.
研究组 & 干预措施
Dapagliflozin
Exposure group
干预措施: Dapagliflozin (Drug)
DPP-4 inhibitor
Reference group
干预措施: DPP-4 inhibitor (Drug)
结局指标
主要结局
Composite outcome of Stroke, MI, and Mortality
时间窗: Through study completion (a median of 120-140 days)
Composite outcome of MI, stroke, and mortality - Please refer to uploaded protocol for full definition due to size limitations.
次要结局
未报告次要终点
研究者
Shirley Vichy Wang
Associate Professor of Medicine
Brigham and Women's Hospital